. Introduction {#s01}
==============

Resistance to chemotherapy and molecular targeted therapies is a major problem facing current cancer research, which severely limits the effectiveness of cancer therapies^[@b1]^. Programmed cell death (PCD) is the regulated cell death mediated by an intracellular program under physiological conditions and has fundamental functions in development, differentiation, and aging. As one of the most conventional PCD types, apoptosis is, therefore, the most obvious target of anti-tumor drugs. However, dysregulated apoptotic signaling allows cancer cells to escape this program and leads to the occurrence of drug resistance^[@b2],[@b3]^, which seriously alters the prognosis of patients. The identification of mechanisms of drug resistance in cancer will provide us with the opportunity to develop rational therapeutic regimens to improve clinical outcomes. Successively discovered types of PCD, including autophagy, necroptosis, pyroptosis, and ferroptosis, have facilitated the search for new therapeutic modalities to overcome drug resistance in cancer.

Autophagy is a regulated process in which the cell disassembles unnecessary or dysfunctional organelles and proteins, thereby meeting the metabolic needs of the cell itself^[@b4],[@b5]^. Autophagy presents an opposing, context-dependent role in cancer. The activation of autophagy suppresses the initiation of tumor growth in the early stages of cancer, while in established tumors, the recycling features of autophagy enable the survival and progression of tumors^[@b6],[@b7]^. Thus, the therapeutic targeting of autophagy in cancer is somewhat controversial^[@b8]^.

Ferroptosis, the newly discovered form of regulated cell death, depends upon intracellular iron accumulation and subsequent lipid peroxidation^[@b9]^. In addition to the induction of tissue injury and protective effects on neurodegenerative diseases^[@b10]--[@b12]^, the activation of ferroptosis also exhibits a remarkable anticancer activity^[@b13]^.

Emerging studies have discovered that autophagy plays an essential role in the induction of ferroptosis^[@b14],[@b15]^. The identification of the interrelationship between ferroptosis and autophagy will not only enable us to obtain a deeper mechanistic understanding of these two types of PCD but also provide new therapeutic targets for cancer treatment. This review provides an up to date overview of the mechanisms of ferroptosis and autophagy, and the possible pathways or compounds that mediate their crosstalk. Then, we discuss the potential utility of targeting this kind of crosstalk to reverse drug resistance in cancer, which is expected to be a promising therapeutic strategy in the future.

. Autophagy overview {#s02}
====================

Autophagy is an evolutionarily conserved process in eukaryotes. It helps the cell maintain homeostasis under stressful conditions by degrading and recycling unnecessary or dysfunctional organelles and proteins in a double-membraned vacuole known as autophagosomes^[@b6],[@b16]^. Autophagy is enhanced in various physiological conditions, such as embryonic development, starvation, and aging. Also, accumulating evidence has suggested that treatments targeting autophagy represent a potential therapeutic strategy in many diseases, including tumors, diabetes, neurodegenerative diseases, and infections, among others^[@b17]^. In general, autophagy plays an important role in cellular homeostasis, organism growth, and the occurrence of diseases^[@b18]^.

A schematic summarizing the process of autophagy is shown in [**Figure 1**](#Figure1){ref-type="fig"}. Morphologically, during the process of autophagy, a preautophagosome first appears in the cytoplasm and gradually develops into an autophagosome, a double-membraned vacuole that contains denatured and necrotic organelles. The outer membrane of the autophagosome fuses with the lysosomal membrane, while the inner membrane and its encapsulated substances enter the lysosomal cavity and are degraded by activated lysosomal hydrolases. This kind of lysosome that fuses with intracellular components is called the autolysosome^[@b4]^.

![Schematic overview of autophagy.](cbm-16-4-630-1){#Figure1}

. Mechanism of autophagy {#s02.01}
------------------------

Autophagy is a continuous and dynamic process that is tightly controlled by autophagy-related genes (Atg). The formation of autophagosomes in mammalian cells consists of two ubiquitin-like modification processes involving autophagy-related protein Atg3, Atg5, Atg7, Atg10, Atg12, and microtubule-associated protein 1A/1B-light chain 3 (LC3), among which Atg12-conjugation and LC3-modification play the most crucial roles. Atg12-conjugation is associated with the formation of preautophagosomes, while LC3-modification is essential for the formation of autophagosomes^[@b19]^. As shown in [**Figure 1**](#Figure1){ref-type="fig"}, Atg12 is first activated by Atg7, transported to Atg10, and then combines with Atg5 to form preautophagosomes with the help of Atg16L. In the process of LC3-modification, proLC3 is first processed into LC3-I in the present of Atg4, activated by Atg7, transported to Atg3, and then processed into LC3-II, the membrane-bound form localized on preautophagosomes and autophagosomes. P62, also known as sequestosme1 (SQSTM1), is a ubiquitin-binding protein that is involved in both the ubiquitin-proteasome system (UPS) and autophagy^[@b20]^. In the process of autophagic turnover of protein aggregates, p62 binds to both polyubiquitinated proteins and LC3, promoting the formation of autophagosomes and the degradation of these proteins^[@b21]^.

The mTOR protein forms two distinct functional complexes, mTORC1 and mTORC2, and it functions as a negative regulator of autophagy. Under nutrient-rich conditions, mTORC1 suppresses autophagy by directly binding and phosphorylating ULK1^[@b22]^. When the cell is stimulated by starvation or rapamycin, ULK1 undergoes rapid dephosphorylation, and activated ULK1 induces Atg13 phosphorylation and autophagy^[@b22],[@b23]^.

PI3Ks and their lipid products are important modulators of phagosome maturation and autophagy^[@b24]^. Mammalian PI3Ks are divided into three classes. Class I PI3Ks inhibit autophagy mainly through the PI3K-Akt-TSCl/TSC2-mTOR pathway^[@b25],[@b26]^. Details are presented in [**Figure 1**](#Figure1){ref-type="fig"}. The formation of autophagosomes also depends on the activation of Class III PI3Ks and Beclin-1^[@b27]^. According to a recent study, S14161, a pan-class I PI3K inhibitor, induces autophagy by enhancing the formation of Beclin-1/Vps34 complex, indicating that the Beclin-1 signaling pathway is also downstream of Class I PI3K^[@b28]^.

. Autophagy and drug resistance in cancer {#s02.02}
-----------------------------------------

As previously stated, autophagy is a process of cellular self-degradation that plays an important role in maintaining homeostasis when cells are confronted with metabolic stress. Based on accumulating evidence, autophagy and drug resistance in cancer are closely linked^[@b29]--[@b31]^. On one hand, one of the most common mechanisms by which cancer cells develop drug resistance is due to apoptosis resistance^[@b32]^, while autophagy is capable of suppressing apoptosis induced by anti-tumor drugs and further promotes drug resistance^[@b29]^. Additionally, autophagy eliminates dysfunctional proteins and organelles, protecting cancer cells treated with cytotoxic agents^[@b30]^. On the other hand, autophagy also exerts anti-tumor effects through as yet uncharacterized mechanisms. Autophagy may reverse drug resistance in apoptosis-tolerant cancer cells by triggering autophagic cell death through a process termed autosis^[@b14],[@b33]^.

The functional interaction between autophagy and apoptosis is regulated by complex networks between multiple pathways. Meanwhile, the mechanism by which cancer cells develop drug resistance involves various factors that have not been completely elucidated. Therefore, therapeutic targeting of autophagy in cancer is sometimes viewed as controversial and more studies are needed in the future.

. Ferroptosis overview {#s03}
======================

In 2003, a new compound, erastin, was reported to selectively kill oncogenic RAS mutant tumor cell lines^[@b34]^. Unexpectedly, erastin-induced cell death does not present classic features of the apoptotic process, such as caspase3 activation, cell shrinkage, chromatin fragmentation, or the formation of apoptotic bodies^[@b34]^. Soon afterward, Yang^[@b35]^ and Yagoda^[@b36]^ found that such cell death is associated with increased levels of intracellular reactive oxygen species (ROS) and can be prevented by iron chelating agents. Meanwhile, Yang^[@b35]^ discovered that another compound, RAS-selective-lethal compound 3 (RSL3), was capable of activating a similar death pathway. In 2012, Dixon et al.^[@b9]^ officially named this form of cell death ferroptosis: an iron-dependent form of non-apoptotic cell death. Based on electron microscopy findings, the mitochondria shrink significantly and membrane density increases during the process of ferroptosis; these features are not observed in apoptosis and autophagy^[@b37]^.

. Mechanism of ferroptosis {#s03.01}
--------------------------

Ferroptosis is characterized by the overwhelming accumulation of lethal intracellular lipid ROS^[@b9]^. When the antioxidant capacity of cells decreases, lipid ROS accumulate within cells, which induces oxidative cell death, or ferroptosis^[@b38]^. Ferroptosis is pivotally controlled by the System Xc-/glutathione/glutathione peroxidase 4 (GPX4) axis^[@b39]^. Meanwhile, metabolic pathways, such as lipid synthesis, iron metabolism, and the mevalonate pathway, also play important roles, as shown in [**Figure 2**](#Figure2){ref-type="fig"}.

![Schematic overview of ferroptosis.](cbm-16-4-630-2){#Figure2}

### System Xc- {#s03.01.01}

System Xc-, a heterodimer composed of SLC7A11 and SLC3A2^[@b40]^, is a cystine/glutamate transporter that mediates the cellular uptake of cystine in exchange for intracellular glutamate^[@b41]^. Inhibition of System Xc- by erastin or its commonly known inhibitor, sulfasalazine (SAS), suppresses cystine uptake and glutathione (GSH) synthesis^[@b9]^. GPX4, the GSH-dependent lipid hydroperoxidase, catalyzes the degradation of hydrogen peroxide and inhibits the production of lipid ROS^[@b42]^. In conclusion, erastin and sulfasalazine decrease GPX4 activity by inhibiting System Xc-, thus reducing the cellular antioxidant capacity and inducing oxidative cell death.

### . GSH synthesis {#s03.01.02}

GSH synthesis requires the participation of glutamate-cysteine ligase (GCL) (formerly known as γ--glutamyl cysteine synthetase, γ-GCS)^[@b43]^. Buthionine-(S, R)-sulfoximine (BSO) decreases GSH synthesis and triggers ferroptosis by inhibiting GCL^[@b44]^. Another important source of cysteine is the conversion of cystathionine to cysteine via the trans-sulfuration pathway, which partially compensates for the erastin-induced decrease in cystine uptake and cystine depletion^[@b45],[@b46]^.

### . GPX4 {#s03.01.03}

Both erastin and RSL3 increase intracellular lipid ROS levels and induce ferroptosis. Unlike erastin, however, RSL3-induced cell death does not show changes in GSH levels. As shown in the 2014 study by Yang et al.^[@b44]^, GPX4 is the target protein of RSL3. Other compounds, such as DPI7 and DPI10, also act directly on GPX4 and suppress its activity. Furthermore, the mevalonate (MVA) pathway acts on GPX4 by regulating the maturity of selenocysteine tRNA. Selenocysteine is a component of the GPX4 active site, and its insertion into GPX4 requires a special transporter -- selenocysteine tRNA^[@b47]^. Modulators of the MVA pathway, such as statins and FIN56, are proposed to positively regulate ferroptosis^[@b48],[@b49]^.

### . PUFAs {#s03.01.04}

Polyunsaturated fatty acids (PUFAs) in cell membranes undergo a series of reactions to form lipid ROS^[@b43],[@b49]^. In the presence of iron, lipid hydroperoxides generated by PUFAs produce toxic lipid free radicals. Moreover, these free radicals transfer protons near PUFAs, initiating a new round of lipid oxidation reactions and further inducing oxidative damage to the cell^[@b50]^. FA synthesis involves multiple metabolic pathways and regulators. Acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) are lipid metabolism-associated genes. ACSL4 acylates arachidonic acid (AA), while LPCAT3 catalyzes the insertion of acylated AA into membrane phospholipids. Studies found that the deletion of these two genes prevented RSL3-induced ferroptosis^[@b51]^, indicating that a substantial amount of membrane lipid PUFAs is required to induce ferroptosis.

### Redox-active iron {#s03.01.05}

The induction of ferroptosis requires the presence of iron. Both lipophilic iron chelators (e.g., ciclopirox olamine, and 2,2-BP) and membrane impermeable iron chelators (e.g., DFA) have been proven to inhibit ferroptosis^[@b43]^. Ferritin is the main intracellular protein that stores iron, and its related genes, ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1), regulate iron storage^[@b52]^. Inhibition of the major transcription factor in iron metabolism -- iron response element binding protein 2 (IREB2) -- increases the expression of FTL and FTH1 and leads to the suppression of erastin-induced ferroptosis^[@b9]^. Heme oxygenase-1 (HO-1)^[@b54]^, transferrin (Tf) and transferrin receptor (TfR)^[@b53],[@b54]^ are other sources of intracellular iron, while the iron transport protein, ferroportin-1 (FPN), removes iron out of from cells^[@b55]^. These proteins are all involved in regulating ferroptosis by modulating iron metabolism and transportation. See [**Figures 2**](#Figure2){ref-type="fig"} and [**3**](#Figure3){ref-type="fig"} for additional details.

![The role of Redox-active iron in ferroptosis and drug resistance.](cbm-16-4-630-3){#Figure3}

. Ferroptosis and drug resistance in cancer {#s03.02}
-------------------------------------------

### . Iron metabolism {#s03.02.01}

An article published in 1993 showed that drug-resistant cells expressed more TfR than drug-sensitive cells, and the downregulation of TfR reversed drug resistance in cancer^[@b56]^. For instance, TfR is expressed at significantly higher levels in CCRF-CEM and K562 leukemia cells than in normal cells^[@b57]^. The combination of anti-tumor drugs and TfR targeting strategies is highly effective in overcoming the resistance of K562 cells to DOX and VER^[@b58]^. A similar phenomenon also exists in endocrine therapy-resistant breast cancer cells, where TfR (CD71) expression is remarkably increased at both mRNA and protein levels^[@b59]^. Transferrin (Tf), the ligand for TfR, reduces the artemisinin (ART) IC50 in multidrug-resistant H69VP SCLC cells to near drug-sensitive levels^[@b60]^. Similarly, Ma et al.^[@b55],[@b61]^ discovered that treating breast cancer cells with lapatinib in combination with siramesine, a lysosome disrupting agent, upregulated Tf and downregulated FPN, thus significantly increasing intracellular iron and inducing ferroptotic cell death. Based on these findings, strategies that target Tf might be a promising method to reverse drug resistance in tumors.

Ferritin is the major intracellular protein that stores iron, and its upregulation has been observed in multiple drug-resistant tumors^[@b62],[@b63]^. Nuclear ferritins protect DNA from damage induced by DNA-alkylating chemotherapeutic drugs, while downregulation of ferritin sensitizes tumor cells to oxidative damage and increases drug sensitivity^[@b63],[@b64]^. Furthermore, ovarian tumor initiated cells (TICs) express lower levels of FPN and higher levels of TfR1 and exhibit enhanced sensitivity to erastin. TICs are believed to represent a small pool of treatment-refractory cells that contribute to drug resistance and tumor recurrence. Thus, strategies targeting ferroptosis by modulating iron levels are expected to solve this clinical problem^[@b65]^. In general, we conclude from the results described above that available redox-active iron is the basis for ferroptosis and its upregulation is one of the most important causes for drug resistance in multiple cancers (see [**Figure 3**](#Figure3){ref-type="fig"} for details).

### . System Xc- {#s03.02.02}

System Xc-, another protein important for ferroptosis induction, has increased expression in many drug-resistant cancer cells^[@b41],[@b66]--[@b69]^. Various stress conditions, including amino acid deprivation, electrophilic agents, oxidative stress, and glucose starvation, activate System Xc- in an NRF2- and ATF4-dependent manner^[@b70],[@b71]^. Moreover, System Xc- is also regulated by tumor suppressors p53 and BAP1 (BRCA1-associated protein1) through the repression of SLC7A11 expression^[@b72]--[@b74]^. Sorafenib, an oral multikinase inhibitor, has also been discovered to induce ferroptosis by blocking System Xc-^[@b9]^. As sorafenib is a clinically approved anti-cancer drug and an efficient ferroptosis inducer, the application of this compound to drug-resistant cancers is worth further study. In conclusion, because System Xc- is upregulated in cancer cells, inhibition of System Xc- expression is a promising therapeutic strategy to increase anti-tumor drug sensitivity.

### . NRF2 pathway {#s03.02.03}

In addition to blocking System Xc-, sorafenib also prevents NRF2 degradation and enhances NRF2 nuclear accumulation by inactivating Kelch-like ECH-associated protein1 (Keap1)^[@b75]^. Nuclear NRF2 promotes the transcription of its downstream targets such as SLC7A11, G6PD, and FTH1^[@b76]^. These genes are involved in lipid peroxidation and iron metabolism, and their transcriptional activation negatively regulates ferroptosis. Inhibition of the p62-Keap1-NRF2 pathway significantly enhances the anti-cancer activity of erastin and sorafenib in hepatocellular carcinoma (HCC) cells^[@b77]^. Activation of the NRF2-ARE (antioxidant response element) pathway is also observed in head and neck cancer cell lines that are resistant to cisplatin and artesunate, while inhibition of this pathway reverses ferroptosis resistance and increases drug sensitivity^[@b78],[@b79]^.

### . Lipid ROS {#s03.02.04}

GSH depletion results in the iron-dependent accumulation of lipid ROS, which is suppressed by antioxidants such as ferrostatin-1 and 6-NA^[@b9],[@b80]^. Increased activity of GSH and GSH-S-transferase (GSTs) is observed in high-grade soft tissue sarcoma (STS) treated with doxorubicin^[@b81]^, as well as in rhabdomyosarcoma tumors resistant to DOX, topotecan and vincristine^[@b82]^. ROS is regarded as the executioner of death in cancer cells undergoing ferroptosis^[@b9]^, thus increasing the source of lipid ROS or reducing the antioxidant capacity of cancer cells is a promising approach to combat drug resistance.

Treatments targeting ferroptosis are expected to be a potential therapeutic strategy to reverse multiple drug resistance in cancers. The possible pathways involved are summarized in [**Table 1**](#Table1){ref-type="table"}, and the currently known inducers and suppressors of ferroptosis are described in [**Table 2**](#Table2){ref-type="table"}.

###### 

Ferroptosis as a potential therapeutic target in various cancers

  Cancer type                                                                                                                                                                       Drug                       Pathway (targets)                     Ferroptosis component        Reference
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------------- ---------------------------- -----------
  Breast cancer                                                                                                                                                                     Tamoxifen                  Transferrin receptor                  Iron metabolism              ^[@b59]^
  Breast cancer                                                                                                                                                                     Faslodex                   Transferrin receptor                  Iron metabolism              ^[@b59]^
  Breast cancer                                                                                                                                                                     Artemisinin                Transferrin                           Iron metabolism              ^[@b83]^
  Breast cancer                                                                                                                                                                     Doxorubicin                Ferritin                              Iron metabolism              ^[@b64]^
  Breast cancer                                                                                                                                                                     Doxorubicin                Ferritin                              Iron metabolism              ^[@b63]^
  Breast cancer                                                                                                                                                                     Cisplatin                  Ferritin                              Iron metabolism              ^[@b63]^
  Breast cancer                                                                                                                                                                     Siramesine and Lapatinib   Ferritin                              Iron metabolism              ^[@b61]^
  Breast cancer                                                                                                                                                                     Ironomycin/AM5             Ferritin                              Iron metabolism              ^[@b84]^
  Breast cancer                                                                                                                                                                     Doxorubicin                Ferroportin-1                         Iron metabolism              ^[@b85]^
  Breast cancer                                                                                                                                                                     Siramesine and Lapatinib   Ferroportin-1                         Iron metabolism              ^[@b55]^
  Breast cancer                                                                                                                                                                     Etoposide                  Iron chelator                         Iron metabolism              ^[@b86]^
  Erythroleukemia                                                                                                                                                                   Doxorubicin                Transferrin                           Iron metabolism              ^[@b87]^
  Promyelocytic leukemia                                                                                                                                                            Doxorubicin                Transferrin                           Iron metabolism              ^[@b86]^
  Leukemia                                                                                                                                                                          Doxorubicin                Transferrin receptor                  Iron metabolism              ^[@b58]^
  Leukemia                                                                                                                                                                          Artemisinin                Transferrin receptor                  Iron metabolism              ^[@b57]^
  Leukemia                                                                                                                                                                          Artemisinin                Transferrin receptor                  Iron metabolism              ^[@b88]^
  Myeloma                                                                                                                                                                           Bortezomib                 Ferritin                              Iron metabolism              ^[@b62]^
  Ovarian cancer                                                                                                                                                                    Platinum                   Ferroportin-1, transferrin receptor   Iron metabolism              ^[@b65]^
  Small-cell lung cancer                                                                                                                                                            Artemisinin                Transferrin                           Iron metabolism              ^[@b60]^
  Epidermoid carcinoma                                                                                                                                                              Vinblastine                Iron chelator                         Iron metabolism              ^[@b85]^
  Glioma                                                                                                                                                                            Carmustine                 H-ferritin                            Iron metabolism              ^[@b89]^
  Glioma                                                                                                                                                                            Temozolomide               System Xc-                            System Xc-                   ^[@b90]^
  Glioma                                                                                                                                                                            Sulfasalazine              System Xc-                            System Xc-                   ^[@b90]^
  Glioma                                                                                                                                                                            Temozolomide               AFT4\--System Xc-                     System Xc-                   ^[@b71]^
  Glioma                                                                                                                                                                            Pseudolaric acid B         p53\--System Xc-                      System Xc-                   ^[@b73]^
  Melanoma                                                                                                                                                                          Vemurafenib                System Xc-                            System Xc-                   ^[@b68]^
  Head and neck cancer                                                                                                                                                              Cisplatin                  System Xc-                            System Xc-                   ^[@b66]^
  Hepatocellular carcinoma                                                                                                                                                          Sorafenib                  System Xc-                            System Xc-                   ^[@b91]^
  Pancreatic cancer                                                                                                                                                                 Gemcitabine                System Xc-                            System Xc-                   ^[@b41]^
  Head and neck cancer                                                                                                                                                              Dihydroartemisinin         GPX4^†^                               Lipid ROS and antioxidants   ^[@b92]^
  Head and neck cancer                                                                                                                                                              Sulfasalazine              Lipid ROS                             Lipid ROS and antioxidants   ^[@b93]^
  Hepatocellular carcinoma                                                                                                                                                          Sorafenib                  Lipid ROS                             Lipid ROS and antioxidants   ^[@b94]^
  Pancreatic cancer                                                                                                                                                                 Gemcitabine                Lipid ROS                             Lipid ROS and antioxidants   ^[@b95]^
  Rhabdomyosarcoma                                                                                                                                                                  Doxorubicin                GSH^‡^                                Lipid ROS and antioxidants   ^[@b96]^
  Small-cell lung cancer                                                                                                                                                            Cisplatin                  GSH^‡^                                Lipid ROS and antioxidants   ^[@b97]^
  Head and neck cancer                                                                                                                                                              Artesunate                 NRF2-ARE^§^ pathway                   NRF2 pathway                 ^[@b77]^
  Head and neck cancer                                                                                                                                                              Cisplatin                  NRF2-ARE^§^ pathway                   NRF2 pathway                 ^[@b78]^
  Hepatocellular carcinoma                                                                                                                                                          Sorafenib                  p62-Keap1-NRF2 pathway                NRF2 pathway                 ^[@b76]^
  Ovarian cancer                                                                                                                                                                    Cisplatin                  Unknown                               Others                       ^[@b67]^
  Head and neck cancer                                                                                                                                                              Sulfasalazine              ALDHs^¶^                              Others                       ^[@b98]^
  † GXP4: glutathione peroxidase 4; ‡ GSH: glutathione; § NRF2-ARE: nuclear factor (erythroid-derived 2) like 2 - antioxidant response element; ¶ ALDHs: aldehyde dehydrogenases.                                                                                                 

###### 

Inducers and suppressors of ferroptosis

  Inducer                                                        Suppressor                                                                                   
  -------------------------------------- ----------------------- --------------------- --------------- ---------------------------- -- ---------------------- ------------------------------------
  Erastin^[@b9]^                         RSL3^¶[@b9]^            Statins^[@b48]^       DpdtC^[@b99]^   Dihydroartemisinin^[@b92]^      Deferoxamine^[@b35]^   Ferrostatin-1^[@b100]^
  Sulfasalazine^[@b9]^                   DPI7^[@b9]^             BSO^†[@b44]^          FAC^‡[@b101]^   Artemisinin^[@b87]^             DFOM^§[@b35]^          Liproxstatin-1^[@b100]^
  Sorafenib^[@b91]^                      DPI10^[@b9]^            Altretamine^[@b35]^                   CN-A and PEITC^[@b95]^          Dp44mT^[@b85]^         α-tocopherol^[@b102]^
  Glutamate^[@b9]^                       FIN56^[@b49]^                                                 PEBP1^[@b103]^                  2,2-BP^[@b9]^          Erythropoietin^[@b104]^
  Lanperisone^[@b38]^                    ML160^[@b38]^                                                 Ardisiacripsin B^[@b103]^       CPX^∫[@b105]^          Trolox^[@b38]^
  SRS13-45^[@b38]^                       Acetaminophen^[@b35]^                                                                                                BHT $\documentclass[12pt]{minimal}
                                                                                                                                                              \usepackage{amsmath}
                                                                                                                                                              \usepackage{wasysym} 
                                                                                                                                                              \usepackage{amsfonts} 
                                                                                                                                                              \usepackage{amssymb} 
                                                                                                                                                              \usepackage{amsbsy}
                                                                                                                                                              \usepackage{upgreek}
                                                                                                                                                              \usepackage{mathrsfs}
                                                                                                                                                              \setlength{\oddsidemargin}{-69pt}
                                                                                                                                                              \begin{document}
                                                                                                                                                              }{}$^\iint$\end{document}$^[@b44]^
  HO-1 $\documentclass[12pt]{minimal}                                                                                                                         Cycloheximide^[@b38]^
  \usepackage{amsmath}                                                                                                                                        
  \usepackage{wasysym}                                                                                                                                        
  \usepackage{amsfonts}                                                                                                                                       
  \usepackage{amssymb}                                                                                                                                        
  \usepackage{amsbsy}                                                                                                                                         
  \usepackage{upgreek}                                                                                                                                        
  \usepackage{mathrsfs}                                                                                                                                       
  \setlength{\oddsidemargin}{-69pt}                                                                                                                           
  \begin{document}                                                                                                                                            
  }{}$^\iiint$\end{document}$^[@b106]^                                                                                                                        
                                                                                                                                                              Aminooxyacetic acid^[@b38]^
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. Interaction between autophagy and ferroptosis {#s04}
===============================================

Accumulating studies have revealed the crosstalk between autophagy and ferroptosis. In this section, we will review these published pathways and molecules to potentially improve our understanding and use of this potential strategy to conquer drug resistance in cancer. A schematic diagram summarizing the crosstalk between autophagy and ferroptosis is shown in [**Figure 4**](#Figure4){ref-type="fig"}.

![Crosstalk between ferroptosis and autophagy. A. Overall mechanisms involving crosstalk between autophagy and ferroptosis. B. The roles of p53 in the crosstalk between autophagy and ferroptosis. C. The roles of Beclin-1 in the crosstalk between autophagy and ferroptosis. D. Other critical molecules and pathways involved in the the crosstalk between autophagy and ferroptosis.](cbm-16-4-630-4){#Figure4}

. Autophagy regulates ferroptosis by ferritin degradation {#s04.01}
---------------------------------------------------------

Ferroptosis has recently been described as an autophagic cell death process, and autophagy plays an essential role in the induction of ferroptosis by regulating cellular iron homeostasis and ROS generation^[@b15],[@b109]^. Ferritin is the major intracellular protein that stores iron. Reactive iron (Fe^2+^) induces toxic Fenton-type oxidative reactions, while the unreactive state (Fe^3+^) stored in ferritin is less harmful^[@b52]^. Under ferroptosis-inducing conditions, such as erastin treatment, autophagy is activated, as confirmed by the conversion of LC3I to LC3II and GFP-LC3 puncta formation^[@b109]^. Autophagy promotes ferritin degradation and thus leads to the release of chelated iron in ferritin, a process known as ferritinophagy. An increase in the cellular labile iron pool induces oxidative stress and eventually results in the occurrence of ferroptosis^[@b109]^. Knockout or knockdown of Atg5 suppresses erastin-induced ferroptosis by decreasing intracellular ferrous iron levels, further indicating that autophagy is essential for ferritin degradation and ferroptosis induction^[@b15]^. Quantitative proteomics identified nuclear receptor coactivator 4 (NCOA4) as the cargo receptor mediating ferritinophagy. Overexpression of NCOA4 increases ferritin degradation and promotes ferroptosis, whereas suppression of NCOA4 expression with multiple shRNAs followed by iron chelation exerts the opposite effect^[@b110]^. On the other hand, ferritin that is not completely saturated with iron helps to preserve a relatively low redox-active iron concentration in the lysosome. Therefore, autophagy of non-iron-saturated ferritin might decrease the sensitivity of the lysosome to oxidative stress, which protects the cell from oxidative injury^[@b111]^. Interestingly, ferroptosis and autophagy were recently shown to induce cell death independently and at different times after siramesine and lapatinib treatment in breast cancer cells^[@b61]^. However, researchers do observe increased ferritin degradation promoted by autophagy. Further studies are needed to better illustrate the cooperation between ferroptosis and autophagy in inducing cell death.

Regulators of ferroptosis are transported to the lysosome and perform their functions via an autophagic process {#s04.02}
---------------------------------------------------------------------------------------------------------------

According to Sun et al.^[@b75],[@b77]^, the Keap1-NRF2 pathway is activated by sorafenib treatment and the expression of its downstream genes, such as Metallothionein-1G (MT1G), is subsequently increased. Metallothioneins (MTs), a class of iron-binding proteins, suppress lysosomal membrane permeabilization (LMP) and protect against various harmful conditions. The upregulation of MTs in combination with starvation-activated autophagy of MTs suppresses the toxicity of Tumor necrosis factor (TNF), a powerful inducer of apoptosis/necrosis, and cycloheximide (CHX), the TNF sensitizer, in hepatoma cells^[@b112]^. Mechanistically, autophagic flux redirects cytoplasmic MTs to the lysosomal compartment where they chelate redox-active iron in the lysosome, thus protecting cells from TNF and CHX toxicity. Therefore, we hypothesize that both autophagy and ferroptosis are involved in drug resistance mediated by MTs. Chemotherapy treatment regulates the expression of MTs. MTs are then transferred to the lysosome through the autophagic process. Next, MTs chelate intralysosomal redox-active iron and protect cells from ferroptosis. Heat shock protein 70 (HSP70) also stabilizes lysosomes under oxidative stress. Autophagy of HSP70 may well mediate the transformation of lysosomal redox-active iron into a non-redox-active form and suppress ferroptosis, similar to autophagy of MTs^[@b113]^.

. Keap-NRF2 pathway {#s04.03}
-------------------

As mentioned above, activation of the p62-Keap1-NRF2 pathway plays an important role in sorafenib-induced ferroptosis in HCC cells^[@b77]^. Meanwhile, the Keap1-NRF2-ARE pathway protects cells from oxidative stress in concert with autophagy^[@b114],[@b115]^. Based on these findings, Keap1-NRF2 might serve as a crucial link between ferroptosis and autophagy.

. ELAV1 {#s04.04}
-------

The RNA-binding protein ELAVL1/HuR plays an important role in regulating ferroptosis in subjects with liver fibrosis^[@b116]^. Ferroptosis-inducing compounds increase levels of the ELAVL1 protein by inhibiting the ubiquitin-proteasome pathway. Meanwhile, upregulated ELAVL1 promotes autophagosome generation and autophagic flux by binding to Beclin-1 mRNA and increasing its stability. The deletion of ELAVL1 increases Beclin-1 mRNA stability and prevents ELAVL1-induced ferroptosis, indicating that autophagy is required for the induction of ferroptosis. These results reveal a new mechanism underlying the relationship between ferroptosis and autophagy. Further investigations are required to determine whether ferritin degradation or activation of the Keap1-NRF2 pathway is involved in this process.

. HO-1 {#s04.05}
------

Heme oxygenase-1 (HO-1), one source of intracellular iron, promotes ferroptosis by inducing lipid peroxidation^[@b34]^. However, Zukor et al.^[@b117]^ found that HO-1 promotes mitochondrial macroautophagy and the trapping of redox-active iron, which might negatively regulate the induction of ferroptosis. Given these contradictory results, further studies are needed to explore the direct role of HO-1 in the interaction between autophagy and ferroptosis.

. p53 {#s04.06}
-----

P53, the best-characterized human tumor suppressor protein, regulates autophagy in a dual fashion. On the one hand, nuclear p53 stimulates autophagy by binding to the promoter region of genes encoding proautophagic modulators such as AMPK, DAPK-1, TSC2 and members of the Bcl-2 family^[@b118]^. In addition, p53 activation inhibits mTOR activity and subsequently promotes autophagy^[@b119]^. On the other hand, p53 in the cytoplasm blocks autophagy via hitherto uncharacterized mechanisms^[@b118]^. Interestingly, nuclear p53 was also recently shown to stimulate ferroptosis in a transcription-dependent manner, inhibiting cystine uptake and sensitizing cells to ferroptosis by repressing the expression of SLC7A11, the gene that encodes System Xc-^[@b120]^. In addition to SLC7A11, several other target genes of p53 have been reported to positively regulate ferroptosis, including GLS2, PTGS2, and STA1^[@b121]^. However, the stabilization of wild-type p53 was recently discovered to delay the onset of ferroptosis by upregulating the expression of its downstream target CDKN1A (encoding p21)^[@b122]^. Furthermore, p53 also inhibits ferroptosis in a transcription-independent manner by binding to the modulator of ferroptosis and lipid metabolism \-- dipeptidyl-peptidase-4 (DPP4)^[@b123]^. Notably, p53 plays a dual regulatory role in both autophagy and ferroptosis, prompting us to question whether this role remains the same in the interaction between autophagy and ferroptosis.

. Beclin-1 {#s04.07}
----------

Beclin-1, the key protein involved in macroautophagy/autophagy, induces lipid peroxidation and promotes ferroptosis by blocking the activity of System Xc- through direct interaction with SLC7A11^[@b124]^. Specifically, activated AMPK phosphorylates Beclin-1 at Ser90/93/96, which is required for the formation of the Beclin-SLC7A11 complex^[@b125]^. Beclin-1 is well known to play essential roles in regulating autophagy and apoptosis. For example, Beclin-1 interacts with Class III PI3Ks to promote the formation of autophagosomes; the BH3 structure of the Beclin-1 protein binds to the antiapoptotic protein Bcl-2/Bcl-xl to inhibit the occurrence of autophagy^[@b126]^. Different Beclin-1 complexes are involved in different pathways and exert different effects on cell death, such as pro-survival effects via autophagy or pro-death effects via ferroptosis. However, the underlying regulatory mechanisms are not yet well understood. Therefore, explorations of how the upstream signaling pathway regulates Beclin-1 to determine its preferred interaction with SLC7A11, Class III PI3Ks, or Bcl-2/Bcl-xl, will be very important.

. GSH {#s04.08}
-----

GSH is a necessary cofactor for GPX4 and occupies a vital position in ferroptosis^[@b42]^. In addition, according to recent research, GSH depletion also induces autophagy, as reflected by increased LC3 expression, numbers of autophagic vacuoles and autophagic flux^[@b103]^. GSH depletion-dependent cell death has been prevented by selective ferroptosis inhibitors (e.g., Fer-1 and Lip-1), as well as autophagy inhibitors (e.g., Baf-A1 and 3-MA). Interestingly, autophagy significantly decreases intracellular GSH levels and vice versa^[@b127]^. Presumably, the mutual effects of GSH and autophagy may modulate the induction of ferroptosis.

. ER stress {#s04.09}
-----------

Inhibition of System Xc- by ferroptotic agents (e.g., erastin and sorafenib) induces the activation of the endoplasmic reticulum (ER) stress response that is modulated by PERK-eIF2α (eukaryotic initiation factor 2α)-ATF4 (activating transcription factor 4) pathway^[@b128]^. On the contrary, another study also finds that ATF4 overexpression leads to System Xc- elevation and inhibits TMZ-induced autophagy^[@b71]^. The dual role of ATF4 in ferroptosis needs further illustration. The ferroptotic agent ART promotes the expression of ATF4-dependent genes, such as CHOP (C/EBP homologous protein)^[@b129]^. CHOP binds to the promoter of PUMA (p52 upregulated modulator of apoptosis) and increases the expression of this protein. PUMA interacts with antiapoptotic Bcl-2 family members such as Bcl-2 and Bcl-xl, thereby possibly indirectly influencing the induction of autophagy by disassembling the Beclin-1/Bcl-2 complex.

. ACSL4 {#s04.10}
-------

Acyl-CoA synthetase long-chain family member 4 (ACSL4), the enzyme involved in arachidonic acid (AA) metabolism, is involved in the mechanism responsible for increased breast cancer cell proliferation, invasion, and migration. Ulises et al.^[@b130]^ identified ACSL4 as a novel activator of the mTOR pathway by showing that it acts on both mTORC1 and mTORC2. ACSL-dependent modulation of phospholipids, particularly AA, were recently shown to be a critical determinant of sensitivity to ferroptosis^[@b131],[@b132]^. Because mTOR protects against excess iron and ferroptosis^[@b133]^, we wondered whether it participates in the ACSL4-mediated modulation of ferroptosis sensitivity.

. STAT3 pathway {#s04.11}
---------------

STAT3 is a positive regulator of ferroptosis in human pancreatic ductal adenocarcinoma (PDAC) by inducing the expression of cathepsin B^[@b134]^, but recent research showed that inhibition of STAT3/GPX4 signaling reactivated ferroptosis and sensitized osteosarcoma cells to cisplatin^[@b135]^. On the other hand, cytoplasmic STAT3 suppresses autophagy by binding to protein kinase B (PKB)^[@b136]^ while autophagy, in turn, promotes IL6-induced phosphorylation of STAT3 and its mitochondrial localization. The underlying roles of STAT3 in the crosstalk between autophagy and ferroptosis are not yet clear and more work is needed.

Crosstalk of autophagy and ferroptosis in drug resistance in cancer {#s05}
===================================================================

The interaction between autophagy and ferroptosis is illustrated above, and the role of these interactions in the response of cancer cells to anti-cancer drugs is briefly summarized.

Autophagy is a cellular catabolic pathway that is involved in lysosomal degradation and recycling of proteins and organelles and thereby is considered an important survival/protective mechanism for cancer cells in response to metabolic stress or anti-cancer drugs. Because multiple studies have shown that autophagy induces ferroptosis and ferroptosis is generally considered a death-inducing pathway, the intensity of autophagy activity may play a vital role in determining the destination of tumor cells treated with anti-cancer drugs.

The unfolded protein response (UPR) is activated following ER stress induced by cellular nutrient depletion, alterations in the redox state, an imbalance in intracellular calcium levels, or dysfunction of posttranslation modifications, and is capable of inducing autophagy^[@b137]^. Combined with the results that inhibition of System Xc- by ferroptotic agents (e.g., erastin and sorafenib) induces the ER stress response^[@b138]^, we speculate that autophagy is first induced when cells are treated with anti-tumor drugs. Only when autophagy reaches a certain intensity will it trigger ferroptosis. Ferritin degradation, chelation of redox-active iron, lysosomal activity, p53 modulation, and the p62-Keap1-NRF2 pathway may be involved in the pathway downstream of autophagy that triggers ferroptosis.

Based on the aforementioned molecular connections between autophagy and ferroptosis, the hypothesis that ferroptosis regulates autophagy is reasonable. To our knowledge, direct evidence supporting this hypothesis is very limited. Indeed, iron deprivation has been shown to induce protective autophagy in multiple cell lines treated with anti-tumor drugs, and autophagy induction is reversed by iron supplementation using ferric ammonium citrate (FAC)^[@b139]^, indicating that ferroptosis may also regulate the occurrence of autophagy. During the process of ferroptosis, lysosome function is postulated to be impaired because of lipid peroxidation, thus suppressing autophagy. On the other hand, the intracellular balance of REDOX (e.g., GSH, GPX4, and lipid ROS) is disrupted during the ferroptotic process, which induces mitochondria damage and may well explain the subsequent onset of autophagy.

Autophagy of MTs prevents TNF- and CHX-induced oxidative stress and toxicity in HCC cells, while inhibition of autophagy via Atg7 knockout combined with Mt1a and/or Mt2a silencing abrogates this protective effect and restores the toxicity of TNF and CHX. Presumably, strategies targeting the autophagy of MTs have the potential to reverse drug resistance by promoting the ferroptotic pathway^[@b112]^. Sorafenib resistance in HCC is reported to be associated with the activation of the p62-Keap1-NRF2 pathway, which plays vital roles in both ferroptosis and autophagy^[@b77],[@b112]^. The knockdown of p62 or inhibition of NRF2 in HCC cells increases the anticancer activity of sorafenib, thus representing a promising strategy to reverse sorafenib resistance.

. Conclusions {#s06}
=============

In this review, we summarize the mechanisms of ferroptosis and autophagy. The effects of most anti-cancer drugs are closely related to the occurrence and regulation of cell death. Autophagy plays an important role in maintaining cell homeostasis by removing excess, dysfunctional or damaged organelles, proteins or pathogens that accumulate in cells. Strategies targeting autophagy are predicted to be a promising modality, while strategies stimulating and inhibiting autophagy are currently under investigation. Ferroptosis consists of a complex set of biochemical reactions involving multiple signaling pathways and the regulation of different genes. The discovery of ferroptosis provides new insights into how tumor cells respond to anti-cancer drugs and provides new approaches to overcome drug resistance in cancer. Autophagy has recently been shown to play an essential role in the induction of ferroptosis. Here, conclusions from relevant studies have been presented and the crosstalk between ferroptosis and autophagy is summarized.

Most existing studies suggest that autophagy promotes drug resistance, while ferroptosis is generally considered to reverse drug resistance in cancer. Therefore, a remaining question is under what circumstances is the balance between ferroptosis and autophagy more biased to ferroptosis to combat drug resistance. More specifically, an unsolved issue is how the cancer cells 'decide' to respond to similar stimuli (anti-cancer drugs) by preferentially undergoing ferroptosis or autophagy. Here, we first propose the crosstalk between ferroptosis and autophagy as a novel and important target for the management of drug resistance in cancer ([**Figure 5**](#Figure5){ref-type="fig"}). Autophagy also exerts its anti-tumor effects via hitherto uncharacterized mechanisms. Based on the data described above, autophagy may induce cell death and reverse drug resistance by promoting ferroptosis, at least in part by inducing ferritin degradation. Conversely, prolonged iron-mediated ROS generation can induce autophagy, which may function as a feedback loop to further induce ferroptosis until cell death occurs. Based on the currently available evidence, we suggest that treatments manipulating the intensity of autophagy to the point where ferroptosis is induced might be a potential therapeutic strategy. This fine-tuned switch depends on the fully delineated molecular mechanism.

![Fine-tune switch between autophagy and ferroptosis in drug resistance.](cbm-16-4-630-5){#Figure5}

Additional studies are still needed to determine how 'ferroptotic' and 'autophagic' processes work alone or synergistically to improve the prognosis of patients with cancer. Actually, many other processes, such as p53-mediated pathways, fatty acid metabolism, iron metabolism, and mitochondrial membrane formation, require the participation of both autophagy and ferroptosis. Once the balance of autophagy and ferroptosis is shifted, the cell may be predisposed to drug resistance. However, the specific interaction between ferroptosis and autophagy is not clearly understood. Therefore, future studies are needed to further explore the underlying mechanisms and related signaling pathways.
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